Invesco’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-108,456
| Closed | -$1.62M | – | 3734 |
|
|
2016
Q2 | $1.62M | Buy |
108,456
+454
| +0.4% | +$5.83K | ﹤0.01% | 2611 |
|
|
2016
Q1 | $1.31M | Buy |
108,002
+8,167
| +8% | +$115K | ﹤0.01% | 2741 |
|
|
2015
Q4 | $1.59M | Buy |
99,835
+7,375
| +8% | +$116K | ﹤0.01% | 2686 |
|
|
2015
Q3 | $1.42M | Buy |
92,460
+15,877
| +21% | +$343K | ﹤0.01% | 2721 |
|
|
2015
Q2 | $1.86M | Sell |
76,583
-53,902
| -41% | -$1.29M | ﹤0.01% | 2675 |
|
|
2015
Q1 | $3.03M | Buy |
130,485
+24,771
| +23% | +$656K | ﹤0.01% | 2332 |
|
|
2014
Q4 | $2.65M | Buy |
105,714
+28,473
| +37% | +$835K | ﹤0.01% | 2350 |
|
|
2014
Q3 | $2.4M | Buy |
77,241
+2,648
| +4% | +$71.7K | ﹤0.01% | 2425 |
|
|
2014
Q2 | $1.93M | Buy |
74,593
+73,993
| +12,332% | +$1.64M | ﹤0.01% | 2604 |
|
|
2014
Q1 | $14K | Sell |
600
-18,850
| -97% | -$412K | ﹤0.01% | 3997 |
|
|
2013
Q4 | $493K | Sell |
19,450
-43,294
| -69% | -$978K | ﹤0.01% | 3458 |
|
|
2013
Q3 | $1.28M | Buy |
62,744
+57,844
| +1,180% | +$1.29M | ﹤0.01% | 2865 |
|
|
2013
Q2 | $103K | Buy |
+4,900
| New | +$87.6K | ﹤0.01% | 3937 |
|
Invesco's SGNT Position: Q3 2016 in Review
Invesco sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 108,456 shares — an estimated $1.62M sold.
Invesco first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $3.03M in Q1 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Invesco reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Invesco sold 108,456 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.62M.
- Invesco first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Invesco's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $3.03M in Q1 2015.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Invesco's 13F filing for Q3 2016, filed 14 Nov 2016.